{"id":32713,"date":"2023-07-10T18:00:00","date_gmt":"2023-07-10T16:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/"},"modified":"2023-07-10T18:00:00","modified_gmt":"2023-07-10T16:00:00","slug":"ipsen-half-year-statement-2023-06-30","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/","title":{"rendered":"Ipsen \u2013 Half year statement \u2013 2023 06 30"},"content":{"rendered":"<p align=\"center\"><b>Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF<\/b><\/p>\n<p align=\"justify\"><b>Paris (France), July 10, 2023 <\/b>&#8211; Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2023, the following resources were included to the dedicated liquidity account:<\/p>\n<ul>\n<li>17,348 shares<\/li>\n<li>\u20ac3,350,842.85 <\/li>\n<\/ul>\n<p align=\"justify\">It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:<\/p>\n<ul>\n<li>12,751 shares<\/li>\n<li>\u20ac3,137,934.80<\/li>\n<\/ul>\n<p align=\"justify\">Between January 1<sup>st<\/sup>, 2023 and June 30, 2023 have been executed:<\/p>\n<ul>\n<li>3,153 purchase transactions<\/li>\n<li>2,820 sell transactions<\/li>\n<\/ul>\n<p align=\"justify\">Under the same period, the volumes traded represented:<\/p>\n<ul>\n<li>360,894 shares and \u20ac38,313,096.35 to the purchase<\/li>\n<li>367,615 shares and \u20ac39,180,843.15 to the sell<\/li>\n<\/ul>\n<p><\/p>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Attachment<\/strong>\n<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=1_XECFTiCc9Gpuj0XDFRsKQI1CY-RhrY-AYa2bYUZOndudkCya3W9l1qUv1i-HmorOIIxq4YBLl3MDK5RiNDS7re11WIHbvyOfxePSfrYB5M-V2ikEizVOdCeu0KCrr6Hc2uvubW_cl8uqr8Clt2J5XmBVMWDrziQRczn3jUKzeSqG_v2B8-vd9GOpDuLw0ZKMaS-AavajIWS3Igr237yQ==\" title=\"IPSEN - PR Half year statement S1 2023 - EN\" rel=\"nofollow noopener\">IPSEN &#8211; PR Half year statement S1 2023 &#8211; EN<\/a>\n      <\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/MDZiN2RmZDEtNzMzOS00M2EwLWE3MjctMDlhN2QxMDU2ZDNhLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[572],"tags":[],"class_list":["post-32713","press_release","type-press_release","status-publish","hentry","category-regulated-info","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen \u2013 Half year statement \u2013 2023 06 30 - United States<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen \u2013 Half year statement \u2013 2023 06 30 - United States\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/MDZiN2RmZDEtNzMzOS00M2EwLWE3MjctMDlhN2QxMDU2ZDNhLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/\",\"url\":\"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/\",\"name\":\"Ipsen \u2013 Half year statement \u2013 2023 06 30 - United States\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/us\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MDZiN2RmZDEtNzMzOS00M2EwLWE3MjctMDlhN2QxMDU2ZDNhLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"datePublished\":\"2023-07-10T16:00:00+00:00\",\"dateModified\":\"2023-07-10T16:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/MDZiN2RmZDEtNzMzOS00M2EwLWE3MjctMDlhN2QxMDU2ZDNhLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MDZiN2RmZDEtNzMzOS00M2EwLWE3MjctMDlhN2QxMDU2ZDNhLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/us\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen \u2013 Half year statement \u2013 2023 06 30\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/us\/#website\",\"url\":\"https:\/\/www.ipsen.com\/us\/\",\"name\":\"United States\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/us\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/us\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/us\/#organization\",\"name\":\"United States\",\"url\":\"https:\/\/www.ipsen.com\/us\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/us\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/2\/2023\/12\/07162616\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/2\/2023\/12\/07162616\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"United States\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/us\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen \u2013 Half year statement \u2013 2023 06 30 - United States","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/","og_locale":"en_US","og_type":"article","og_title":"Ipsen \u2013 Half year statement \u2013 2023 06 30 - United States","og_url":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/","og_site_name":"United States","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/MDZiN2RmZDEtNzMzOS00M2EwLWE3MjctMDlhN2QxMDU2ZDNhLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/","url":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/","name":"Ipsen \u2013 Half year statement \u2013 2023 06 30 - United States","isPartOf":{"@id":"https:\/\/www.ipsen.com\/us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MDZiN2RmZDEtNzMzOS00M2EwLWE3MjctMDlhN2QxMDU2ZDNhLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","datePublished":"2023-07-10T16:00:00+00:00","dateModified":"2023-07-10T16:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/MDZiN2RmZDEtNzMzOS00M2EwLWE3MjctMDlhN2QxMDU2ZDNhLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MDZiN2RmZDEtNzMzOS00M2EwLWE3MjctMDlhN2QxMDU2ZDNhLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/us\/press-releases\/ipsen-half-year-statement-2023-06-30\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/us\/"},{"@type":"ListItem","position":2,"name":"Ipsen \u2013 Half year statement \u2013 2023 06 30"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/us\/#website","url":"https:\/\/www.ipsen.com\/us\/","name":"United States","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/us\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/us\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/us\/#organization","name":"United States","url":"https:\/\/www.ipsen.com\/us\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/us\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/2\/2023\/12\/07162616\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/2\/2023\/12\/07162616\/Latest_Ipsen-logo_168x48.svg","caption":"United States"},"image":{"@id":"https:\/\/www.ipsen.com\/us\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/us\/wp-json\/wp\/v2\/press_release\/32713"}],"collection":[{"href":"https:\/\/www.ipsen.com\/us\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/us\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/us\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/us\/wp-json\/wp\/v2\/press_release\/32713\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/us\/wp-json\/wp\/v2\/media?parent=32713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/us\/wp-json\/wp\/v2\/categories?post=32713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/us\/wp-json\/wp\/v2\/tags?post=32713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}